EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection

Phillip Chan iD, Bohyung Yoon, Donn Colby, Eugène Kroon, Carlo Sacdalan, Somchai Sriplienchan, Suteeraporn Pinyakorn, Jintanat Ananworanich, Victor Valcour, Sandhya Vasan, Denise Hsu, Nittaya Phanuphak und 2 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Phillip Chan und 13 weiteren Autor:innen. Beteiligte Einrichtung: South East Asia Research Collaboration in HIV, Institute of HIV Research and Innovation, Bangkok, Thailand. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIMH NIH HHS, NCATS NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Efavirenz (EFV)- and dolutegravir (DTG)-based antiretroviral therapy (ART) is the former and current recommended regimen for treatment-naive individuals with human immunodeficiency virus type 1 (HIV-1). Whether they impact the immunological and neuropsychiatric profile differentially remains unclear.

Methods

This retrospective analysis included 258 participants enrolled during acute HIV-1 infection (AHI). Participants initiated 1 of 3 ART regimens during AHI: EFV-based (n = 131), DTG-based (n = 92), or DTG intensified with maraviroc (DTG/MVC, n = 35). All regimens included 2 nucleoside reverse-transcriptase inhibitors and were maintained for 96 weeks. CD4+ and CD8+ T-cell counts, mood symptoms, and composite score on a 4-test neuropsychological battery (NPZ-4) were compared.

Results

At baseline, the median age was 26 years, 99% were male, and 36% were enrolled during Fiebig stage I–II. Plasma viral suppression at weeks 24 and 96 was similar between the groups. Compared with the EFV group, the DTG group showed greater increments of CD4+ (P < .001) and CD8+ (P = .015) T-cell counts but a similar increment of CD4/CD8 ratio at week 96. NPZ-4 improvement was similar between the 2 groups at week 24 but greater in the DTG group at week 96 (P = .005). Depressive mood and distress symptoms based on the Patient Health Questionnaire and distress thermometer were similar between the 2 groups at follow-up. Findings for the DTG/MVC group were comparable to those for the DTG group vs the EFV group.

Conclusions

Among individuals with AHI, 96 weeks of DTG-based ART was associated with greater increments of CD4+ and CD8+ T-cell counts and improvement in cognitive performance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsHumansMaleAdultFemaleRetrospective StudiesBenzoxazinesHeterocyclic Compounds, 3-RingCognitionDolutegravirAlkynesCyclopropanes

Stichwörter der Autor:innen

T-cell countacute HIV infectionantiretroviral therapycognitive functiondepression

Substanzen

BenzoxazinesHeterocyclic Compounds, 3-RingAnti-HIV AgentsDolutegravirefavirenzAlkynesCyclopropanes

Autor:innen und Institutionen

  • South East Asia Research Collaboration in HIV, Institute of HIV Research and Innovation, Bangkok, Thailand.
  • Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.
  • US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
  • Department of Global Health, Amsterdam University Medical Centers, Amsterdam Institute for Global Health and Development, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Neurology, Memory and Aging Center, University of California-San Francisco, San Francisco, California, USA.

ORCID-Profile: Phillip Chan

Förderung

  • NIMH NIH HHS
  • NCATS NIH HHS
  • NINDS NIH HHS
  • Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
  • US Department of Defense
  • NINDS
  • NIMH
  • International NeuroHIV Cure Consortium

Zitieren

APA

Chan, P., Yoon, B., Colby, D., Kroon, E., Sacdalan, C., Sriplienchan, S., Pinyakorn, S., Ananworanich, J., Valcour, V., Vasan, S., Hsu, D., Phanuphak, N., Paul, R., & Spudich, S. (2023). Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac466

Vancouver

Chan P, Yoon B, Colby D, Kroon E, Sacdalan C, Sriplienchan S, et al. Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac466

BibTeX
@article{Chan2023,
  author = {Chan, Phillip and Yoon, Bohyung and Colby, Donn and Kroon, Eugène and Sacdalan, Carlo and Sriplienchan, Somchai and Pinyakorn, Suteeraporn and Ananworanich, Jintanat and Valcour, Victor and Vasan, Sandhya and Hsu, Denise and Phanuphak, Nittaya and Paul, Robert and Spudich, Serena},
  title = {Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac466}
}
Kostenlos starten →